Skip to main content
. 2025 May 29;16:1610967. doi: 10.3389/fimmu.2025.1610967

Table 2.

Characteristics and outcomes of participants categorized according to PLR tertiles.

Variables PLR T1 (n=333) PLR T2 (n=333) PLR T3 (n=336) p-value
PLR 48.91 (36.99, 57.82) 91.80 (80.75, 109.02) 232.74 (167.94, 333.86) <0.001
Personal characteristics
 Age (years) 71.68 (62.69,78.74) 71.24 (63.97,78.65) 77.48 (67.21,85.11) <0.001
 Gender (%) 0.251
  Female 152 (45.65) 161 (48.35) 175 (52.08)
  Male 181 (54.35) 172 (51.65) 161 (47.92)
Scores
 OASIS 32.00 (26.00,37.00) 32.00 (26.00,37.00) 33.00 (27.00,39.00) 0.133
 GCS 15.00 (14.00,15.00) 15.00 (14.00,15.00) 15.00 (14.00,15.00) 0.584
 CCI 4.00 (3.00,6.00) 5.00 (3.00,7.00) 6.00 (5.00,8.00) <0.001
Comorbidities
 Respiratory failure (%) <0.001
  No 285 (85.59) 254 (76.28) 242 (72.02)
  Yes 48 (14.41) 79 (23.72) 94 (27.98)
 Diabetes (%) 0.232
  No 238 (71.47) 224 (67.27) 220 (65.48)
  Yes 95 (28.53) 109 (32.73) 116 (34.52)
 Hypertension (%) 0.591
  No 330 (99.10) 329 (98.80) 330 (98.21)
  Yes 3 (0.90) 4 (1.20) 6 (1.79)
 Renal disease (%) <0.001
  No 270 (81.08) 239 (71.77) 207 (61.61)
  Yes 63 (18.92) 94 (28.23) 129 (38.39)
 Sepsis (%) <0.001
  No 320 (96.10) 297 (89.19) 247 (73.51)
  Yes 13 (3.90) 36 (10.81) 89 (26.49)
 Paraplegia (%) 0.962
  No 324 (97.30) 325 (97.60) 327 (97.32)
  Yes 9 (2.70) 8 (2.40) 9 (2.68)
Laboratory tests
 Lymphocytes (109/L) 2.63 (2.17,3.51) 1.66 (1.34,2.05) 0.81 (0.57,1.08) <0.001
 Monocytes (109/L) 0.56 (0.35,0.88) 0.56 (0.33,0.86) 0.70 (0.40,1.07) 0.008
 Neutrophils (109/L) 10.49 (7.98,14.28) 8.89 (6.49,12.93) 9.49 (6.69,13.80) <0.001
 Platelets (109/L) 125.00 (102.00,153.00) 157.00 (127.00,186.33) 193.72 (155.75,242.25) <0.001
 NM 5.41 (2.95,10.40) 4.76 (2.37,9.04) 6.50 (3.18,12.71) <0.001
 NP 1302.14 (892.70,1936.40) 1341.90 (904.20,2107.28) 1867.86 (1141.35,2995.47) <0.001
 MP 66.40 (38.16,114.70) 80.85 (44.67,143.28) 144.23 (68.81,223.14) <0.001
 NLR 3.75 (2.78,5.10) 5.71 (3.80,7.77) 11.49 (7.96,20.07) <0.001
 MLR 0.21 (0.13,0.31) 0.35 (0.19,0.51) 0.84 (0.46,1.41) <0.001
 SII 482.66 (336.37,675.60) 821.86 (611.51,1198.62) 2241.60 (1345.33,3987.76) <0.001
 SIRI 2.10 (1.14,3.77) 2.81 (1.45,5.91) 7.61 (3.44,16.17) <0.001
 AIRI 256.00 (128.19,477.01) 444.15 (237.56,894.27) 1479.03 (642.50,3370.15) <0.001
Outcomes
 ICU LOS (days) 2.51 (1.40,4.87) 2.31 (1.33,4.33) 2.59 (1.33,5.16) 0.201
 30‐day ICU mortality (%) <0.001
 Alive 329 (98.80) 324 (97.30) 287 (85.42)
 Death 4 (1.20) 9 (2.70) 49 (14.58)

Medians and interquartile ranges (25th and 75th percentiles) were calculated for continuous variables and frequencies and percentages for categorical variables. The Wilcoxon rank sum test was used to compare group differences for continuous variables and Chiiablesss tests for categorical variables.

AIRI, aggregate index of systemic inflammation response; CCI, charlson comorbidity index; GCS, glasgow coma scale; ICU, intensive care unit; LOS, length of stay; MLR, monocyte-to-lymphocyte ratio; MP, monocyte × platelet; NLR, neutrophil-to-lymphocyte ratio; NM, neutrophil × monocyte; NP, neutrophil × platelet; OASIS, oxford acute severity of illness score; PLR, platelet-to-lymphocyte ratio; T, tertile; SII, systemic immune-inflammation index; SIRI, systemic inflammation response index.